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Abstract
Background: Recent investigations demonstrated many genetic contributions to the development of human age-
related hearing impairment (ARHI), however, reports of factors associated with a reduction in the ARHI risk are rare.
Folate metabolism is essential for cellular functioning. Despite the extensive investigations regarding the roles of
folate metabolism related gene polymorphisms in the pathophysiology of complex diseases, such as cancer,
cardio-cerebrovascular disease, and atherosclerosis, little is known about the association with ARHI. The aim of this
study is to investigate the effects of the methionine synthase (MTR) A2756G and methylenetetrahydrofolate
reductase (MTHFR) C677T gene polymorphisms on the risk of hearing impairment in middle-aged and elderly
Japanese.
Methods: Data were collected from community-dwelling Japanese adults aged 40-84 years who participated in
the Longitudinal Study of Aging biennially between 1997 and 2008. We analyzed cumulative data (5,167 samples
in accumulated total) using generalized estimating equations.
Results: The MTHFR 677T allele was significantly associated with a reduced risk of hearing impairment only when
the subjects were wild-type homozygotes for MTR A2756G. The per-T allele odds ratio of MTHFR for the risk of
developing hearing impairment was 0.7609 (95% CI: 0.6178-0.9372) in the MTR AA genotype. In addition, a
subgroup analysis demonstrated that the favorable effect of the MTHFR 677T allele on the risk of developing
hearing impairment was independent of folate and homocysteine level, whereas plasma total homocysteine level
was independently associated with an increased risk of developing hearing impairment. The interactive effect of
gene polymorphisms associated with folate metabolism may modify the risk of developing hearing impairment
after middle age. These results contribute to the elucidation of the causes of ARHI.
Conclusions: The present study has found that the MTHFR 677T allele has a favorable effect on a risk of hearing
impairment in the middle-aged and elderly population, only when the individuals were wild-type homozygotes for
MTR A2756G.
Background
Presbycusis is one of the most common sensory impair-
ments affecting the elderly and is a multifactorial pro-
cess that involves a multitude of intrinsic and extrinsic
factors. Recent investigations demonstrated many
genetic contributions to human age-related hearing
impairment (ARHI) [1-7].
Folate metabolism is essential for cellular functioning
because it provides one-carbon donors for the de novo
synthesis of purines and pyrimidines, which are necessary
for RNA and DNA synthesis, and provides methyl
groups, which are necessary for the remethylation
of homocysteine and for methylation reactions such as
DNA methylation [8,9]. The enzyme methylenetetr-
ahydrofolate reductase (MTHFR) irreversibly catalyzes
the conversion of 5,10-methylenetetrahydrofolate
(5,10-methyleneTHF) to 5-methyltetrahydrofolate
(5-methylTHF), a methyl donor. Methionine synthase
(MTR) catalyzes the remethylation of homocysteine to
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methionine. Folate in the form of 5,10-methyleneTHF
donates a methyl group to uracil, converting it to thymi-
dine, which is used for DNA synthesis and repair [10].
(See Additional file 1, Figure S1.)
Folates cannot be synthesized de novo by mammals.
Polymorphisms in genes encoding critical enzymes in
folate metabolism play important and interrelated roles
in the pathophysiology of cancer [9-13], cardio-cerebro-
vascular disease, atherosclerosis [14], pregnancy loss,
renal failure [15], diabetic retinopathy [16], and the pro-
gression of Alzheimer’s disease [17].
The MTHFR C677T polymorphism (rs1801133),
which results in an alanine-to-valine substitution, is one
of the most extensively investigated functional poly-
morphisms of genes encoding one-carbon metabolism
enzymes and occurs frequently in Caucasian and Asian
populations. This substitution results in a 30% decrease
in MTHFR activity in heterozygotes and a 60% decrease
in MTHFR activity in homozygotes [18].
Although reports are not uniformly consistent, this
polymorphism has been shown to modify the risk of
developing several cancers in a site-specific manner
[13,19,20]. It decreases the risk of colorectal cancer,
hepatocellular carcinoma, cervical cancer, and certain
leukemias and lymphomas. In contrast, it increases the
risk of cancer of the breast, endometrium, esophagus,
stomach, pancreas, and bladder [13]. Epidemiological
evidence indicates that this polymorphism has a protec-
tive effect against colorectal cancer in individuals with
an adequate or high status of folate and nutrients
involved in one-carbon metabolism [21-23].
The most common MTR gene polymorphism is MTR
A2756G (rs1805087), which results in a substitution of
aspartic acid for glycine and decreases methionine
synthase activity [24]. This polymorphism increases the
cellular homocysteine level [25], resulting in DNA hypo-
methylation [26].
The MTHFR and MTR polymorphisms have attracted
interest as causes of sudden sensorineural hearing loss
(SSNHL) [27-29]. We reported results from a nested
case-control study using data from the National Institute
for Longevity Sciences - Longitudinal Study of Aging
(NILS-LSA) that showed that the T allele of MTHFR
C677T is associated with susceptibility to SSNHL. How-
ever, little has been reported on the association between
folate pathway gene polymorphisms and ARHI. Durga et
al. investigated the effects of folate status and the
MTHFR C677T polymorphism on hearing in middle-
aged and elderly subjects [30].
In this study, we investigated whether the MTHFR
C677T (rs1801133) and MTR A2756G (rs1805087)
polymorphisms are associated with hearing impairment




The subjects used in this study were derived from the
NILS-LSA, an ongoing population-based biennial survey
of a cohort of approximately 2,200 persons. The NILS-
LSA is a comprehensive and interdisciplinary study to
observe age-related changes and consists of various geron-
tological and geriatric measurements, such as medical
examinations, blood chemical analysis, body composition,
anthropometry, physical function, nutritional analysis, psy-
chological tests, and visual and auditory function. The sub-
jects of the NILS-LSA were randomly selected from
resident registrations, stratified by both age and sex. The
numbers of men and women recruited were similar, and
age at baseline was 40 years to 79 years, with similar num-
bers of participants in each decade of age (40s, 50s, 60s,
and 70s). Details of the NILS-LSA are described elsewhere
[5]. The study protocol was approved by the Ethical Com-
mittee of the National Center for Geriatrics and Gerontol-
ogy and written informed consent was obtained from all
participants. Those who did not consent to have blood
samples taken and those who did not complete the hear-
ing test were excluded. As the MTHFR C677T and MTR
A2756G polymorphisms can be associated with SSNHL,
participants who reported a history of ear disease were
also excluded. Gene polymorphisms were examined using
blood samples taken at the initial examination. The base-
line subjects of this study were 1,426 adults (722 men and
704 women) aged 40-79 years who completed the first-
wave examinations of NILS-LSA between November 1997
and April 2000. Of these, 1,103 (77.3%) took part in the
second-wave examination, 994 (69.7%) took part in the
third-wave examination, 855 (60.0%) participated in the
fourth-wave examination, and 789 (55.3%) participated in
the fifth-wave examination. The mean number of repeat
visits was 3.6. The total number of visits, including repeat
visits, was 5,167; the participants from whom the data
were derived were 40-84 years of age and took part in the
NILS-LSA between November 1997 (the first wave) and
July 2008 (the fifth wave).
The genotype frequencies, in participants of the NILS-
LSA at baseline examination both before and after employ-
ing exclusion criteria of the present analyses, were not sig-
nificantly different from those expected based on the
Hardy-Weinberg equilibrium in the MTHFR C677T and
MTR A2756G polymorphisms (chi-square test, P > .05).
Ethical approval
Ethical Committee of the National Center for Geriatrics
and Gerontology.
Identification number: #14, #52, #74.
Genetic analyses
Genomic DNA was extracted from peripheral blood
lymphocytes using a standard procedure. The genotype
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(A or G) at position 2756 of the MTR gene and the gen-
otype (C or T) at position 677 of the MTHFR gene were
determined using an allele-specific-primer polymerase
chain reaction (ASP-PCR) method (Toyobo Gene Analy-
sis, Tsuruga, Japan).
• MTHFR genotype analysis
The single nucleotide polymorphism region of the gene
was amplified by PCR using two allele-specific-primers
(ASPs): (C-specific primer, 5’-GAAGGTGTCTGCGG
GAXCC-3’; T-specific primer, 5’-GAGAAGGTGT
CTGCGGGAXTC-3’) and a biotin-labeled common
antisense primer (5’-biotin-GAATGTGTCAGCCT
CAAAGAAA-3’). Amplified allele-specific DNA pro-
ducts were used for colorimetric genotyping. For
MTHFR genotyping, two types of wells conjugated with
the allele-specific C-type probe (5’-TCTGCGGGAXCC-
GATTTCAT-3’) or T-type probe (5’-TCTGCGG
GAXTCGATTTCAT-3’) were prepared. The amplified
DNA product was denatured with NaOH and added to
each well. Then, it was hybridized at 37°C for 30 min-
utes with hybridization buffer containing formamide.
After the wells were thoroughly washed, alkaline phos-
phatase-conjugated streptavidin was added to each well,
and the plate was incubated at 37°C for 15 minutes.
After the wells were washed, 0.8 mmol/L WST-1 [2-(4-
iodophenyl)-3-(4-nitrophenyl)-5-(2,4-di-sulfophenyl)-2H-
tetrazolium, monosodium salt] and 0.4 mmol/L BCIP
(5-bromo-4-chloro-3-indolyl phosphate p-toluidine salt),
a substrate for alkaline phosphatase, were added and
colorimetry was performed. The genotypes were identi-
fied according to the absorbance signal ratio between C
type-specific and T type-specific wells. Further details of
MTHFR genotyping in the NILS-LSA are supplied else-
where [31].
• MTR genotype analysis
The polymorphic region of the gene was amplified using
PCR and two ASPs labeled at the 5” end, either with
fluorescein isothiocyanate (A-specific primer, 5’-GGAA-
GAATATGAAGATATTAGACAGXAC-3’) or with
Texas Red (G-specific primer, 5’-GAAGAATATGAAGA
TATTAGACAGXGC-3’) and a biotin-labeled common
antisense primer (5’-biotin-CTACCACTTACCTTGA
GAGACTCAT-3’). The reaction mixture (25 μL) con-
tained 20 ng of DNA, 5 pmol of each primer, 0.2 mmol/
L of each deoxynucleoside triphosphate, 5.0 mmol/L
MgCl2, and 1 U of rTaq DNA polymerase (Toyobo,
Osaka, Japan) in the appropriate DNA polymerase buf-
fer. The amplification protocol consisted of an initial
denaturation at 95°C for 5 minutes, 35 cycles of dena-
turation at 95°C for 30 seconds, annealing at 65°C for
30 seconds, extension at 72°C for 30 seconds, and a
final extension at 72°C for 2 minutes. Amplified DNA
was incubated in a solution containing streptavidin-con-
jugated magnetic beads in the wells of a 96-well plate at
room temperature. The plate was placed on a magnetic
stand, and the supernatants were then collected from
each well, transferred to the wells of a 96-well plate con-
taining 0.01 mol/L NaOH, and fluorescence was then
measured using a microplate reader (Spectra Fluor;
Tecan Co., Tokyo, Japan) at excitation and emission
wavelengths of 485 nm and 538 nm, respectively, for
fluorescein isothiocyanate and 584 nm and 612 nm,
respectively, for Texas Red.
Measures
Air-conduction pure-tone thresholds at octave intervals
from 0.5 kHz to 8 kHz were measured in a sound-proof
booth by trained examiners using a standardized proto-
col and a diagnostic audiometer (AA-73A and AA-78;
Rion, Tokyo, Japan). For analyses of supraliminal levels,
thresholds in excess of the predetermined output level
according to the JIS (Japanese Industrial Standards T
1201) calibration plus an additional 5 dB were treated as
levels. The average hearing threshold level (AHT) of the
better ear at frequencies of 0.5, 1, 2, and 4 kHz was
used as an index of hearing status among genotypes.
Hearing impairment was defined as an AHT greater
than 25 dB according to World Health Organization
grades [32].
Venous blood samples were collected with the consent
of the participants for genetic and other blood analyses.
Blood samples were collected early in the morning after
at least 12 hours of fasting. Plasma total homocysteine
concentration was determined using high-performance
liquid chromatography and fluorimetric detection [33].
The serum concentration of folate was determined using
a chemiluminescent enzymatic reaction using Access
(Beckman Coulter Inc., Fullerton, CA).
Most of the moderator variables for analyses (history
of occupational noise exposure, lifetime smoking, heart
disease, hypertension, and diabetes) were self-reported.
Histories of occupational noise exposure and lifetime
smoking were categorized as never vs. ever. Individual
medical histories were obtained using questionnaires.
Each of the cited moderators was treated as a binary
variable (presence vs. absence). Body mass index (BMI)
was calculated as weight (kg) divided by height (m2).
Statistical analysis
Statistical analyses were conducted using Statistical Ana-
lysis System version 9.1.3 (SAS Institute, Cary, NC).
Univariate analyses of categorical variables according to
hearing impairment status were performed using the
chi-square test and baseline data. The chi-square test
was also conducted to assess the independency of geno-
type distribution of the two polymorphisms in the base-
line data. Cumulative data were analyzed using
generalized estimating equations (GEEs), which take
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into account the dependency of repeated observations
within subjects. GEE models were fitted using the GEN-
MOD procedure of SAS. The GENMOD procedure fits
generalized linear models. The correlation structure was
specified as autoregressive.
Genotypes were coded as follows: wild-type homozy-
gotes, AA for MTR and CC for MTHFR, heterozygotes,
AG for MTR and CT for MTHFR, and mutant homozy-
gotes, GG for MTR and TT for MTHFR. In an explora-
tory analysis to assess the effect of MTR A2756G and
MTHFR C677T on hearing impairment, MTR, MTHFR,
and the MTHFR by MTR interaction were set as inde-
pendent variables using the GENMOD procedure. Then,
based on the results of the exploratory analysis, odds
ratios (ORs) for the additive genetic models of MTHFR
polymorphisms according to MTR genotypes with the
risk of hearing impairment were analyzed with adjust-
ment for age, sex, smoking status, BMI, and histories of
occupational noise exposure, heart disease, hypertension,
and diabetes. The additive genetic model, which is the
prevailing analytical model in genetic epidemiology,
assumes that there is a linear gradient in risk with
increasing numbers of mutated alleles. The per-allele
OR for the risk of developing hearing impairment was
determined using the additive genetic model.
Data from only 1,146 of the 1,426 baseline participants
could be used for a subgroup analysis in which blood
folate and homocysteine levels were included as vari-
ables in the statistical model because blood folate and
homocysteine levels were measured during first-wave
examinations. Comparison of serum folate and plasma
total homocysteine levels according to MTHFR geno-
types by MTR genotypes was conducted using a general
linear model. A multiple logistic regression was then
performed to obtain ORs for hearing impairment in
subjects with the MTHFR C677T polymorphism by
MTR genotypes as a subgroup analysis. In this analysis,
age, sex, smoking status, BMI, and histories of occupa-
tional noise exposure, heart disease, hypertension, and
diabetes were denoted as possible influential variables.
ORs per ng/mL increase in serum concentration of
folate and per nmol/mL increase in plasma total homo-
cysteine concentration were also estimated.
All values are expressed as the mean ± standard devia-
tion unless otherwise specified. A null-hypothesis prob-
ability of < 0.05 was regarded as statistically significant.
Results
The general characteristics and genotype frequencies of
the baseline subjects are presented in Table 1 according
to hearing impairment status. As stated before, partici-
pants who reported a history of ear disease were
excluded since the MTHFR C677T and MTR A2756G
polymorphisms are associated with SSNHL. No
significant differences in hearing impairment frequency
were observed between the MTR and MTHFR geno-
types according to univariate analysis. As expected, the
frequency of hearing impairment was greater in males
than in females. The prevalence of hearing impairment
was greater in subjects who had histories of occupa-
tional noise exposure, heart disease, hypertension, and
diabetes, and smoking and in older subjects. The distri-
butions of MTR A2756G and MTHFR C677T at base-
line were not significantly associated with each other
(chi-square test, p > 0.05).
The genotype frequencies of the two polymorphisms
in the cumulative data are presented according to hear-
ing impairment status in Table 2. Hearing impairment
frequencies were 15.8% for the MTR AA genotype,
30.1% for the MTR AG genotype, and 37.2% for the
MTR GG genotype. An exploratory analysis of the
effects of MTR, MTHFR, and the MTHFR by MTR
interaction on hearing impairment with no adjustments
conducted using the GENMOD procedure showed that
the main effects of MTR and MTHFR and the interac-
tion effect were significant (p = 0.0318, 0.0022, and
0.0076, respectively). After adjustment for moderators
(age, sex, smoking status, BMI, history of occupational
noise exposure, heart disease, hypertension, and dia-
betes), the main effect of MTHFR was still significant (p
= 0.0230), but the main effect of MTR was not signifi-
cant (p = 0.2736). The interactive effect was almost sig-
nificant (p = 0.0856). The per-allele OR for the risk of
developing hearing impairment according to the additive
genetic model of MTHFR polymorphisms by MTR gen-
otypes with adjustment for moderators is shown in
Table 3 with 95% confidence intervals (CIs). The per-T
allele OR of MTHFR for the risk of developing hearing
impairment was 0.7609 (95% CI: 0.6178-0.9372) in the
MTR AA genotype. The risk of hearing impairment
decreased significantly with an increase in the frequency
of the T allele of MTHFR independently of moderators,
but only in the MTR AA genotype. Per-T allele ORs
were not statistically significant for other MTR
genotypes.
In a subgroup analysis, the mean level of serum folate
in 1,146 subjects was 5.6 ± 2.6 ng/mL, and that of
plasma total homocysteine was 11.0 ± 5.1 nmol/mL.
Levels of serum folate and plasma total homocysteine
according to MTR and MTHFR genotypes are shown in
Table 4. Serum folate levels were significantly different
among the MTHFR genotypes in the heterozygous and
homozygous MTR 2756A genotypes, and levels of
plasma total homocysteine differed significantly among
the MTHFR genotypes in all MTR genotypes. The
results of multiple logistic regression are presented in
Table 5. In the MTR 2756A homozygous genotype, the
MTHFR 677T allele showed an effect opposite to a high
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homocysteine level. The MTHFR 677T allele was signifi-
cantly associated with a reduction in the risk of develop-
ing hearing impairment when associated with the MTR
2756AA genotype; this association was independent of
folate or homocysteine level. Homocysteine level was
associated with an increase in the risk of hearing impair-
ment, but folate level was not. No significant association
with a risk of hearing impairment was observed under
conditions of the MTR 2756AG genotype. Data for the
MTR 2756GG genotype were discarded because the
small number of cases rendered the analysis of dubious
validity.
Discussion
The main findings of our study were that the risk of
developing hearing impairment in middle-aged and
elderly subjects is influenced by an interaction between
the MTR A2756G and MTHFR C677T gene poly-
morphisms and that the MTHFR 677T allele is asso-
ciated with a reduced risk of hearing impairment, but
Table 1 General characteristics and genotype frequencies at baseline according to hearing impairment status
Variable Total N (%) Hearing impairment No hearing impairment
N % N % p
1426 275 19.3 1151 80.7
MTR A2756G
AA (wild-type homozygotes) 939 (65.8) 174 18.5 765 81.5 0.2459
AG (heterozygotes) 436 (30.6) 94 21.6 342 78.4
GG (mutant homozygotes) 51 (3.6) 7 13.7 44 86.3
A allele 81.1% 442 19.1 1872 80.9 -
G allele 18.9% 108 20.1 430 79.9
MTHFR C677T
CC (wild-type homozygotes) 529 (37.1) 115 21.7 414 78.3 0.1954
CT (heterozygotes) 681 (47.8) 122 17.9 559 82.1
TT (mutant homozygotes) 216 (15.1) 38 17.6 178 82.4
C allele 61.0% 352 20.2 1387 79.8 -
T allele 39.0% 198 17.8 915 82.2
Gender
Male 173 24.0 549 76.0 <.0001
Female 102 14.5 602 85.5
Age
<60 19 2.8 660 97.2 <.0001
≥60 256 34.3 491 65.7
Occupational noise exposure
Yes 111 37.4 186 62.6 <.0001
No 164 14.5 965 85.5
History of hypertension
Yes 98 26.8 268 73.2 <.0001
No 177 16.7 883 83.3
History of heart disease
Yes 42 27.3 112 72.7 0.0078
No 233 18.3 1039 81.7
History of diabetes
Yes 41 35.3 75 64.7 <.0001
No 234 17.9 1076 82.1
Smoking
Current and ex-smoker 144 23.0 481 77.0 0.0015
Nonsmoker (Never smoked) 131 16.4 670 83.6
Obesity
BMI ≥ 25 55 17.4 261 82.6 0.3371
BMI < 25 220 19.8 890 80.2
N = 1426 (Age, mean ± SD: 59.8 ± 10.9).
Uchida et al. BMC Medical Genetics 2011, 12:35
http://www.biomedcentral.com/1471-2350/12/35
Page 5 of 9
only when the MTR A2756G genotype is a wild-type
homozygote (AA).
We recently reported that the T allele of the MTHFR
C677T gene polymorphism may be associated with an
increased risk of SSNHL [29]. In the present analysis,
the MTHFR 677 T allele decreased the risk of hearing
impairment among the middle-aged and elderly, pro-
vided that the MTR A2756G genotype was AA. These
apparently contradictory effects of the MTHFR C677T
polymorphism on hearing are consistent with the results
of Durga et al [30]. They examined the association
between elevated plasma homocysteine level and its
determinants with hearing levels in middle-aged and
elderly subjects. Their hypothesis was that an elevated
concentration of homocysteine and its determinants,
including the MTHFR 677TT genotype, would be asso-
ciated with poor hearing. Contrary to their hypothesis,
the results demonstrated that MTHFR 677TT homozy-
gotes had 5 dB (p = 0.037) and 2.6 dB (p = 0.021) lower
PTA-high and PTA-low hearing thresholds, respectively,
than subjects with a 677C allele when their folate status
was above the median. They found that high serum
folate concentrations were associated with better hearing
in MTHFR 677TT homozygotes, whereas high serum
folate concentrations were associated with poorer hear-
ing in CC homozygotes. In the present study, the
MTHFR variant allele conferred an advantage with
respect to hearing when the MTR A2756G genotype
was the wild type, which probably maintains MTR enzy-
matic activity at a higher level than in the variant [24].
Studies of carcinogenesis showed that an impaired MTR
reaction, as observed in vitamin B12 deficiency or in
cases of chronic ethanol ingestion, results in the contin-
uous conversion of 5,10-methylene-THF to 5-methyl-
THF. Thus, a substantial proportion of cellular folate is
converted into a metabolically unavailable form, which
results in a functional folate deficiency [34]. The MTR
2756A allele may prevent functional folate deficiency via
MTR activity.
As referred to previously, the MTHFR 677T allele has
favorable and unfavorable effects on human health. The
conflicting effects of the MTHFR C677T polymorphism
on carcinogenesis may be resolved as follows. When the
dietary supply of folate and related nutrients is suffi-
cient, individuals carrying variant MTHFR genotypes
may be at reduced risk of cancer because high intracel-
lular levels of 5,10-methyleneTHF may prevent imbal-
ances in the nucleotide pool during DNA synthesis,
thereby ensuring that DNA replication occurs with high
Table 2 Genotype frequencies of two polymorphisms in
cumulative data according to hearing impairment status
MTR MTHFR Hearing impairment No hearing impairment
A2756G C677T N % N %
CC 317 25.7 915 74.3
AA CT 354 21.4 1297 78.6
TT 77 15.8 410 84.2
CC 137 21.5 501 78.5
AG CT 184 24.6 564 75.4
TT 69 30.1 160 69.9
CC 16 25.4 47 74.6
GG CT 10 13.2 66 86.8
TT 16 37.2 27 62.8
Total N 1180 22.8 3987 77.2
N = 5167.
Table 3 Odds ratios and 95% confidence intervals for additive genetic model of MTHFR polymorphism by MTR
genotypes with risk of hearing impairment analyzed by generalized estimating equations in cumulative data
MTR MTHFR
CC (T = 0) CT (T = 1) TT (T = 2) p
N 1933 2475 759
AA (wild-type homozygotes) 3370 1 0.7609 (0.6178-0.9372)/T-allele 0.0102
AG (heterozygotes) 1615 1 1.1040 (0.7963-1.5305)/T-allele 0.5528
GG (mutant homozygotes) 182 1 1.3231 (0.6332-2.7649)/T-allele 0.4565
N = 5167.
Parenthetical reference shows 95% confidence interval.
[Moderator variable].
age, sex, smoking status, BMI.
histories of occupational noise exposure, heart disease, hypertension, and diabetes.
Table 4 Comparison of serum folate and plasma total
homocysteine levels according to MTR and MTHFR
genotypes
MTHFR
MTR CC CT TT p
AA 6.0 ± 2.6 5.6 ± 2.6 4.8 ± 2.1 <.0001
folate AG 6.0 ± 3.2 5.7 ± 2.1 4.8 ± 2.0 0.0159
(ng/mL) GG 6.5 ± 3.2 5.3 ± 2.2 4.1 ± 1.8 0.0970
AA 10.5 ± 3.3 10.6 ± 3.9 13.8 ± 10.6 <.0001
homocysteine AG 10.0 ± 2.5 10.9 ± 3.8 13.2 ± 8.8 0.0001
(nmol/mL) GG 8.9 ± 1.7 10.1 ± 2.2 15.0 ± 6.8 0.0006
N = 1146.
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fidelity [9,13]. DNA methylation is crucial for epigenetic
modification of the genome, which is involved in the
regulation of many cellular processes. Some MTHFR
variants are associated with DNA hypomethylation [35].
The degree of DNA methylation modulates the risks of
various cancers as a consequence of gene-environment
interactions [36]. The MTHFR 677T allele may affect
disease susceptibility in a beneficial or an adverse
manner.
Durga et al. explained the etiology of AHRI in terms
of mitochondrial damage [37]. It was proposed that
damage to mitochondrial DNA accumulates over time
and that once a critical threshold is attained, the mito-
chondria are rendered bioenergetically inefficient and
cells undergo apoptosis. Individuals with the MTHFR
677TT genotype may have increased levels of thymidy-
late synthesis, which may directly reduce the probability
of DNA mutations by ensuring a smaller pool of uracil
and, hence, a decreased likelihood of uracil misincor-
poration into DNA. In addition, MTHFR 677TT homo-
zygotes may have high levels of 10-formylTHF, which
may protect mitochondrial integrity by reducing cyto-
chrome c [38] and, because of its structural lability, may
exert antioxidant-like effects [39].
This study has certain limitations. A major weakness
of this study is that homocysteine and folate levels were
available for only 22% of the cumulative data because of
cost restriction. Also lab tests for vitamin B12 and/or
methylmalonic acid were not performed, which are
additional metabolic parameters potentially influenced
by MTR enzymatic action. Current opinion is that the
677 C-to-T variant exerts its effect via an elevated
homocysteine level as described as ‘the homocysteine
hypothesis’ [14]. On the other hand, the homocysteine
hypothesis and homocysteine-lowering therapeutic
approaches to vascular disease have been questioned in
recent years. Secondary prevention trials have failed to
confirm the benefit of homocysteine-lowering therapy
on cardiovascular disease [40,41]. Antoniades et al. pro-
posed that folic acid and its circulating metabolite, 5-
methylTHF, have direct effects on vascular function in
humans, independent of their effects on plasma homo-
cysteine level [42,43]. Therefore, data on changes in
metabolites of the folate and homocysteine pathways
and the status of B vitamins would have strengthened
this study.
Another issue that has created some confusion is the
seemingly contradictory effects of the MTHFR 677T
allele on SSNHL vs. ARHI in the NILS-LSA study popu-
lation. We reported that the MTHFR 677T allele may be
associated with an increased risk of SSNHL and that it
may be associated with a reduced risk of hearing impair-
ment later in life if the individuals are wild-type homo-
zygotes for MTR A2756G. No plausible explanation for
this contradiction can be offered at this stage. However,
given that one of the many hypotheses on the etiology
of SSNHL involves impaired perfusion and ischemic
damage to the cochlea, the MTHFR 677T allele may
contribute to risk of an acute vascular event in the
cochlea. On the other hand, the MTHFR 677T allele
has certain advantages for the better-hearing ear in
homozygous MTR 2756AA individuals, which are inde-
pendent of plasma total homocysteine level. Bilateral
hearing impairment as defined by the World Health
Organization requires the presence of a hearing impair-
ment in the better-hearing ear. Therefore, the better-
hearing ear was used in our study in order not to over-
estimate individuals with only one affected ear as sub-
jects with ARHI. The contribution of the MTHFR 677T
allele to the affected ear in SSNHL may differ from its
contribution to the better-hearing ear in middle-aged
and elderly people.
Table 5 Odds ratios and 95% confidence intervals for additive genetic model of MTHFR polymorphism by MTR
genotypes, folate and homocysteine with risk of hearing impairment analyzed by a multiple logistic regression in a
subgroup analysis
No. ORs (95% confidence interval)
MTR Hearing impairment No hearing impairment MTHFR/T-allele folate homocysteine
AA 126 626 0.602 * 0.946 1.066 *
(0.421-0.861) (0.861-1.039) (1.021-1.113)
AG 71 281 1.379 0.941 0.953
(0.830-2.292) (0.816-1.084) (0.893-1.017)
GG 7 35 Data not shown (the validity of the model fit is questionable due to small number).
N = 1146.
Asterisk shows statistically significance (p < 0.05). Parenthetical reference shows 95% confidence interval.
[Moderator variable].
age, sex, smoking status, BMI.
histories of occupational noise exposure, heart disease, hypertension, and diabetes.
Uchida et al. BMC Medical Genetics 2011, 12:35
http://www.biomedcentral.com/1471-2350/12/35
Page 7 of 9
Although genetic contributions to ARHI have been
increasingly reported, significant associations between
gene polymorphisms and a reduced risk of ARHI are
rare. The results of this study may help to elucidate the
complex mechanisms responsible for ARHI. This is an
observational epidemiological design, which helps us to
understand the factors that determine the presence or
absence of disorder. Hypotheses derived from our
results need to be verified by further basic and applied
researches.
Conclusions
The present study has found that the MTHFR 677T
allele has a favorable effect on a risk of hearing impair-
ment in the middle-aged and elderly population, only
when the individuals were wild-type homozygotes for
MTR A2756G. In addition, the favorable impact of the
MTHFR 677T allele on the risk of developing hearing
impairment in the MTR 2756AA genotype was indepen-
dent of blood folate and homocysteine levels. These
results may contribute to our understanding of the
pathology of ARHI.
Additional material
Additional file 1: Supplemental figure S1. Simplified scheme of the
role of MTR and MTHFR in folate metabolism and one-carbon
transfer reactions. The file contains a scheme which provides a
comprehensible information regarding favorable and unfavorable effects
of MTHFR 677T allele on biological activity.
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